Snapshot from Jul 23, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Zydus, Apollo, Guardant Partner for...
Business partnership

Zydus, Apollo, Guardant Partner for Cancer Test in India

Analysis based on 8 articles · First reported Jul 03, 2026 · Last updated Jul 03, 2026

Sentiment
70
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The partnership between Astec LifeSciences, Apollo Hospitals, and Guardant Health to introduce a multi-cancer detection test in India is expected to positively impact the healthcare and pharmaceutical markets. Shares of Astec LifeSciences and Apollo Hospitals rose following the announcement, indicating investor confidence in the potential for improved cancer diagnostics and market expansion in India.

Pharmaceuticals Healthcare Biotechnology
Event Summary

Astec LifeSciences has partnered with Apollo Hospitals and Guardant Health to introduce the Shield Multi-Cancer Detection (MCD) blood test in India. This methylation-based test screens for 10 common cancers in individuals aged 45 and above who are at average risk, using a single blood sample. The collaboration aims to expand access to innovative cancer screening technology across India, where cancer incidence and mortality rates are high, and screening rates remain low. The test has received Breakthrough Device Designation from the United States — Food and Drug Administration. This initiative is expected to enhance early cancer detection, improve treatment outcomes, and contribute to proactive healthcare in India.

Key Actions
100 Astec LifeSciences signed MoU Apollo Hospitals
90 Astec LifeSciences partnered Guardant Health
80 Apollo Hospitals will offer
50 United States — Food and Drug Administration granted designation
Entities Involved
stock
Astec LifeSciences
Astec LifeSciences has partnered with Apollo Hospitals and Guardant Health to introduce the Shield Multi-Cancer Detection test in India, expanding its oncology diagnostics portfolio and market reach. Its shares rose following the announcement.
Importance 100.0 Sentiment 70.0
stock
Apollo Hospitals
Apollo Hospitals, through its Apollo Hospitals group, is collaborating with Astec LifeSciences to offer the Shield Multi-Cancer Detection test, enhancing its diagnostic services and commitment to proactive healthcare. Its shares also saw an increase.
Importance 90.0 Sentiment 60.0
stock
Guardant Health
Guardant Health has an exclusive agreement with Astec LifeSciences to make its Shield Multi-Cancer Detection test available in India, expanding its global market presence for innovative cancer screening technology.
Importance 80.0 Sentiment 60.0
cnt
India
India will benefit from increased access to advanced multi-cancer detection screening, potentially improving public health outcomes by enabling earlier diagnosis and treatment of various cancers.
Importance 70.0 Sentiment 50.0
per
Prathap C. Reddy
As Chairman of Apollo Hospitals Group, Prathap C. Reddy emphasized the importance of this collaboration in advancing accessible cancer screening solutions for the people of India.
Importance 40.0 Sentiment 50.0
per
Sharvil Patel
As Managing Director of Astec LifeSciences, Sharvil Patel highlighted the company's focus on increasing awareness and expanding access to diagnostic tools through this partnership.
Importance 40.0 Sentiment 50.0
per
Simranjit Singh
As CEO of Guardant Health AMEA, Simranjit Singh noted that earlier detection can transform cancer outcomes and this collaboration will help increase access to screening technology in India.
Importance 30.0 Sentiment 50.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration granted Breakthrough Device Designation to the Shield Multi-Cancer Detection test, recognizing its potential, though this does not imply regulatory approval or clearance.
Importance 20.0 Sentiment 0.0
Relationships
Astec LifeSciences related ↔ India
Apollo Hospitals related ↔ India
India related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.